MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3

Klaus Hollmig,Sarah Waheed,Bijay Nair,Jeff Haessler,Nathan Petty,Mauricio Pineda-Roman,Yazan Alsayed,F. Van Rhee,J Crowley,Bart Barlogie

MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3

2009

Klaus Hollmig
Sarah Waheed
Bijay Nair
Jeff Haessler
Nathan Petty
Mauricio Pineda-Roman
Yazan Alsayed
F. Van Rhee
J Crowley
Bart Barlogie

8595 Background: We have previously reported on the variables associated with the development of MDS-CA in the context of autologous transplant-supported high-dose therapy regimens for MM (Barlogie...

Keywords:

Oncology
Multiple myeloma
Consolidation Chemotherapy
cons
Surgery
Internal medicine
Medicine
Pathology
post transplant
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations